Postnatal glucocorticosteroid therapy for treatment and prevention of neonatal chronic lung disease

Bibliography

• COLE CH, FRANTZ ID: Role of postnatal steroids for neonatal chronic lung disease. In: Current Topics in Neonatology Edition 2. Hansen TN, McIntosh N, (Eds.) WB. Saunders, London, UK (1997):256–280.
   Google Scholar
• •Detailed review of postnatal glucocorticoid therapy through 1997.
   Google Scholar
• BANCALARI E: Corticosteroids and neonatal chronic lung disease. Eur. j Pediatr. (1998) 157 (Suppl. 1) :S31–S37.
   Google Scholar
• YOUNG TE: Postnatal steroid therapy in neonates. Curr. Opin. Pediatr. (1997) 9:184–188.
   PubMedGoogle Scholar
• OGAWA Y, TAKASAKI J, ITAKURA Y, SHIMIZU: Epidemi-ology and classification of chronic lung disease. Pediatr. Pulmonol (1997) 16:25–26
   Google Scholar
• FARRELL PA AND FIASCONE JM: Bronchopulmonary dysplasia in the 1990s: A Review for the Pediatrician. Curr. Probl. Pediatr. (1997) 27(4) :129–172.
   PubMedGoogle Scholar
• •Excellent recent overview of bronchopulmonary dysplasia.
   Google Scholar
• HISLOP AA: Bronchopulmonary dysplasia: Pre- and postnatal influences and outcome. Pediatr. Pulmonol (1997) 23:71–75.
   PubMed Web of Science ®Google Scholar
• ZIMMERMAN JJ: Bronchoalveolar inflammatory pathophysiology of bronchopulmonary dysplasia. Clin. Perinatol. (1995) 22:429–456.
   PubMed Web of Science ®Google Scholar
• •Excellent review of the inflammatory mediators of bronchopulmonary dysplasia, or chronic lung disease.
   Google Scholar
• PIERCE M R, BANCALARI E: The role of inflammation in the pathogenesis of bronchopulmonary dysplasia. Pediatr. Pulmonol (1995) 19:371–378.
   PubMed Web of Science ®Google Scholar
• •Excellent discussion of the role of inflammation in the pathogenesis of bronchopulmonary dysplasia.
   Google Scholar
• STENMARK KR, EYZAGUIRRE M, WESTCOTT JY: Potentialrole of eicosanoids and platelet-activating factor in the pathophysiology of BPD. Am. Rev. Respir. Dis. (1987) 136:770–772.
   PubMed Web of Science ®Google Scholar
• GRONECK P, SOTZE-SPEER B, OPPERMAN M, EIFFERT H,SPEER CP: Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high risk preterm neonates. Pediatrics (1994) 93:712–718.
   PubMed Web of Science ®Google Scholar
• WATTS CL, FANAROFF AA, BRUCE MC: Elevation of fibronectin levels in lung secretions of infants with respiratory distress syndrome and development of bronchopulmonary dysplasia. J. Pediatr. (1992) 120:614–620.
   PubMed Web of Science ®Google Scholar
• KOTECHA S, WANGOO A, SILVERMAN M, SHAW RJ: Increase in the concentration of transforming growth factor a-1 in bronchoalveolar lavage fluid before development of chronic lung disease of prematurity. J. Pediatr. (1996) 128:464–469.
   PubMed Web of Science ®Google Scholar
• WATTERBERG KL, CARMICHAEL DF, GERDES JS, WERNERS, BACKSTROM C, MURPHY S: Secretory leukocyte protease inhibitor and lung inflammation in developing bronchopulmonary dysplasia. J. Pediatr. (1994) 125:264–269.
   PubMed Web of Science ®Google Scholar
• BAGCHI A, VISCARDI RM, TACIAK V et al: Increasedactivity of interleukin-6 but not tumor necrosis factor-a in lung lavage of premature infants is associ-ated with development of bronchopulmonary dysplasia. Pediatr. Res. (1994) 36:244–252.
   PubMed Web of Science ®Google Scholar
• WATTERBERG KL, DEMERS LM, SCOTT SM, MURPHY S:Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics (1996) 97:210–215.
   PubMed Web of Science ®Google Scholar
• WATTS DH, KROHN MA, HILLIER SL, ECHENBACH DA: The association of occult amniotic fluid infection with gestational age and neonatal outcome among women in preterm labor. Obstet. Gynecol (1992) 79:351–357.
   PubMed Web of Science ®Google Scholar
• GRONECK P, GOTZE-SPEER B SPEER CP: Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth. Arch. Dis. Child. (1996) 74:51–55.
   Web of Science ®Google Scholar
• COALSON JJ, WINTER V, DELEMOS RA: Decreased alveolarization in baboon survivors with bronchopul-monary dysplasia. Am. J. Respir. Crit. Care Med. (1995) 152:640–646.
   PubMed Web of Science ®Google Scholar
• ARIAGNO RL: Bronchopulmonary dysplasia. In: Use ofSteroids. Merritt Ta, Northway Wh, Boynton Br (Edss): Blackwell Scientific, Boston, USA (1988) 375–402.
   Google Scholar
• GERDES JS, HARRIS MC, POLIN RA: Effects of dexametha-sone and indomethacin on elastase, al-proteinase inhibitor and flbronectin in bronchoalveolar lavage fluid from neonates. J. Pediatr. (1988) 113:727–731.
   PubMed Web of Science ®Google Scholar
• GRONECK P, REUSS D, GOETZE-SPEER B, SPEER CP:Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease. J. Pediatr. (1993) 122:938–944.
   PubMed Web of Science ®Google Scholar
• WATTS CL, BRUCE MC: Effect of dexamethasone therapy on flbronectin and albumin levels in lung secretions of infants with bronchopulmonary dysplasia. j Pediatr. (1992) 121:597–607.
   PubMed Web of Science ®Google Scholar
• WANG JY, YEH TF, LIN YJ, CHEN WY, LIN CH: Early postnatal dexamethasone therapy may lessen lung inflammation in premature infants with respiratory distress syndrome on mechanical ventilation. Pediatr. Pulmonol. (1997) 23:193–197.
   PubMed Web of Science ®Google Scholar
• MURCH SH, MACDONALD TT, WOOD CB, COSTELOE KL:Tumor necrosis factor in the bronchoalveolar secretions of infants with respiratory distress syndrome and the effect of dexamethasone treatment. Thorax (1992) 47:44–47.
   PubMed Web of Science ®Google Scholar
• TOWNLEY RG, REEB R, FITZGIBBONS T, ADOLPHSON RL:The effect of corticosteroid on the beta-adrenergic receptors in bronchial smooth muscle. J. Allergy Clin. Immunol. (1970) 45:118.
   Google Scholar
• YODER MC, CHUA R, TEPPER R: Effect of dexametha-sone on pulmonary inflammation and pulmonary function of ventilator-dependent infants with bronchopulmonary dysplasia. Am. Rev. Respir. Dis (1991) 143:1040–1048.
   Google Scholar
• GLADSTONE IM, EHRENKRANZ RA, JACOBS HC: Pulmonary function tests and fluid balance in neonates with chronic lung disease during dexamethasone treatment. Pediatrics (1989) 84:1072–1076.
   PubMed Web of Science ®Google Scholar
• FRANK L, LEWIS PI, SOSENKO IRS: Dexamethasone stimulation of fetal rat lung antioxidant enzyme activity in parallel with surfactant stimulation. Pediat-rics (1985) 75: 569–574.
   PubMed Web of Science ®Google Scholar
• DELEMOS RA, SHERMETA DW, KNELSON JH, KOTAS R, AVERY ME: Acceleration of appearance of pulmonary surfactant in the fetal lamb by administration of corticosteroid. Am. Rev. Respir. Dis. (1970) 102:459–461.
   PubMed Web of Science ®Google Scholar
• WILSON JW: Treatment and prevention of pulmonary cellular damage with pharmacologic dose of corticos-teroid. Surg. Gynecol. Obstel (1972) 134:678–681.
   Google Scholar
• NORTHWAY WH JR, ROSAN RC, PORTER DY: Pulmonary disease following respirator therapy in hyaline membrane disease: Bronchopulmonary dysplasia. N Engl. J. Med. (1967) 276:357.
   PubMed Web of Science ®Google Scholar
• •Original description of bronchopulmonary dysplasia.
   Google Scholar
• KRAMER LI, HULTZEN C: The role of steroids in early bronchopulmonary dysplasia (BPD). Pediatr. Res. (1978) 12:564A.
   Google Scholar
• GRYLACK LL, SCANLON KB, SCANLON JW: Corticos-teroid treatment of fourteen newborns with bronchopulmonary dysplasia. Clin. Res. (1979) 27:819A.
   Google Scholar
• POMERANCE J, PURI AR: Treatment of neonatal bronchopulmonary dysplasia with steroids. Pediatr. Res. (1980) 14:649A.
   Google Scholar
• SCHICK JB, GOETZMAN BE, SMITH LE et al.: Corticos-teroid responsiveness in chronic lung disease of prematurity. Pediatr. Res. (1981) 15:680A.
   Google Scholar
• DONN SM, FAIX RG, BANAGALE RC: Dexamethasone for bronchopulmonary dysplasia. Lancet (1983) 2:460.
   PubMed Web of Science ®Google Scholar
• MAMMEL MC, GREEN TP, JOHNSON DE et al.: Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia. Lancet (1983) 1:1356–1358.
   PubMed Web of Science ®Google Scholar
• AVERY GB, FLETCHER AB, KAPLAN M, BRUDNO DS: Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia. Pediatrics (1985) 75:106–111.
   PubMed Web of Science ®Google Scholar
• HARKAVY KL, SCANLON JW, CHOWDHRY PK, GRYLACK LJ: Dexamethasone therapy for chronic lung disease in ventilator- and oxygen-dependent infants: a controlled trial. J. Pediatr. (1989) 115:979–83.
   PubMed Web of Science ®Google Scholar
• ARIAGNO RL, SWEENEY TJ, BALDWIN RB, INGUILO D, MARTIN D: Dexamethasone effects on lung function and risk in 3-week-old ventilatory dependent preterm infants. Am. Rev. Respir. Dis. (1987) 135:125A.
   Google Scholar
• NOBEL-JAMIESON CM, REGEV R, SILVERMAN M: Dexamethasone in neonatal chronic lung disease: Pulmonary effects and intracranial complications. Eur. j Pediatr. (1989) 148:365–367.
   PubMed Web of Science ®Google Scholar
• COLLABORATIVE DEXAMETHASONE TRIAL GROUP: Dexamethasone Therapy in Neonatal Chronic Lung Disease: An international placebo-controlled trial. Pediatrics (1991) 88:421–427.
   PubMed Web of Science ®Google Scholar
• HALLIDAY HL, EHRENKRANZ RA: Delayed (>3 weeks) postnatal corticosteroids for chronic lung disease in preterm infants (Cochrane Review). In: The Cochrane Library. Issue 1 (1999).
   Google Scholar
• •Very good systematic review of late-onset glucocorticoid therapy.
   Google Scholar
• CUMMINGS JJ, D'EUGENIO DB, GROSS SJ: A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia. N Engl. J. Med. (1989) 320:1505–1510.
   PubMed Web of Science ®Google Scholar
• PAPILE LA, TYSON JE, STOLL BJ et al.: A multicenter trialof two dexamethasone regimens in ventilator-dependent premature infants. N Engl. J. Merl. (1998) 338:1112–1118.
   PubMed Web of Science ®Google Scholar
• KOTHADIA JM, O'SHEA TM, ROBERTS D, AURINGER ST, WEAVER G, DILLARD RG: Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants. Pediatrics (1999) 104:22–27.
   PubMed Web of Science ®Google Scholar
• BHUTA T, OHLSSON A: Systematic review and meta-analysis of early postnatal dexamethasone for prevention of chronic lung disease. Arch. Dis. Child Fetal Neonatal Ed. (1998) 79:F26–F33.
   Google Scholar
• ARIAS-CAMISON JM, LAU J, COLE CH, FRANTZ ID: Meta-analysis of dexamethasone therapy started in the first 15 days of life for prevention of chronic lung disease in premature infants. Pediatric Pulmonol. (1999) 28:167–174.
   PubMed Web of Science ®Google Scholar
• HALLIDAY HL, EHRENKRANZ RA: Early postnatal (96 hours) corticosteroids for preventing chronic lung disease in preterm infants. In: The Cochrane Library. Issue] (1999).
   Google Scholar
• HALLIDAY HL, EHRENKRANZ RA: Moderately early (7–14 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. In: The Cochrane Library. Issue 1. (1999).
   Google Scholar
• BROZANSKI BS, JONES JG, GILMOUR CH et al: Effect of pulse dexamethasone therapy on the incidence and severity of chronic lung disease in the very low birth weight infant. JPediatr. (1995) 126:769–776.
   PubMed Web of Science ®Google Scholar
• DURAND M, SARDESAI S, MCEVOY C: Effects of early dexamethasone therapy on pulmonary mechanics and chronic lung disease in very low birth weight infants: a randomized controlled trial. Pediatrics (1995) 95:584–590.
   PubMed Web of Science ®Google Scholar
• KARI MA, HEINONEN K, IKONEN RS, KOIVISTO M, RAIVIO KO: Dexamethasone treatment in preterm infants at risk for bronchopulmonary dysplasia. Arch. Dis. Child (1993) 68:566–569.
   PubMed Web of Science ®Google Scholar
• BLOOMFIELD FH, KNIGHT DB, HARDING JE: Side effects of 2 different dexamethasone courses for preterm infants at risk of chronic lung disease: A randomized trial. J. Pediatr. (1998) 133:395–400.
   PubMed Web of Science ®Google Scholar
• YEH TF, TORRE JA, RASTOGI A, ANYEBUNO MA, PILDES RS: Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study. J. Pediatr. (1990) 117:273–282.
   PubMed Web of Science ®Google Scholar
• SANDERS RJ, COX C, PHELPS DL, SINKIN RA: Two doses of early intravenous dexamethasone for the preven-tion of bronchopulmonary dysplasia in babies with respiratory distress syndrome. Pediatric Res.(1994) 36:122–128.
   PubMed Web of Science ®Google Scholar
• SINKIN RA, DWECK HS, HORGAY MJ, GALLAGHER J, COX C, PHELPS DL: Early dexamethasone for the prevention of BPD in surfactant treated babies with RDS. Pediatr. Res. (1998) 43:195 Abstract.
   Google Scholar
• SHINWELL ES, KARPLUS M, SMORA E et al.: Failure of early postnatal dexamethasone to prevent chronic lung disease in infants with respiratory distress syndrome. Arch. Dis. Child. (1996) 74:F33–F37.
   Google Scholar
• SUSKE G, OESTREICH K, VARNHOLT V, LASCH P, KACHEL W: Influence of early postnatal dexamethasone therapy on ventilator dependency in surfactant-substituted preterm infants. Acta Paediatr. (1996) 85:713–718.
   PubMed Web of Science ®Google Scholar
• RASTOGI A, AKINTORIN SM, BEZ ML, MORALES P, PILDES RS: A controlled trial of dexamethasone to prevent bronchopulmonary dysplasia in surfactant-treated infants. Pediatrics (1996) 98:204–210.
   PubMed Web of Science ®Google Scholar
• YEH TF, LIN YJ, HSIEH WS et al.: Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial. Pediat-rics (1997) 100(4) (http://www.pediatrics.org/cgi/content/ful1/100/4/e3).
   Google Scholar
• SUBHEDAR NV, RYAN SW, SHAW NJ: Open randomised controlled trial of inhaled nitric oxide and early dexamethasone in high risk preterm infants. Arch. Dis. Child (1997) 77:F185–F190.
   Web of Science ®Google Scholar
• KOPELMAN AE, MOISE AA, HOLBERT D, HEGEMIER SE: A single very early dexamethasone dose improves respiratory and cardiovascular adaptation in preterm infants. J. Peds. Sept. (1999) 135 (3):345–350.
   PubMed Web of Science ®Google Scholar
• TAPIA JL, RAMIREZ R, CIFUENTES J et al.: The effect of early dexamethasone administration on bronchopul-monary dysplasia in preterm infants with respiratory distress syndrome. JPediatr. (1998) 132:48–52.
   PubMed Web of Science ®Google Scholar
• KOVACS L, DAVIS GM, FAUCHER D, PAPAGEORGIOU: Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity. Acta Paediatr. (1998) 87:792–798.
   PubMed Web of Science ®Google Scholar
• LIN JY, YEH TF, HSIEH WS, CHI YC, LIN HC AND LIN CH:Prevention of chronic lung disease in preterm infants by early postnatal dexamethasone therapy. Pediatr. Pulmonol (1999) 27:21–26.
   PubMed Web of Science ®Google Scholar
• GARLAND JS, ALEX CP, PAULY TH et al.: A three-day course of dexamethasone therapy to prevent chronic lung disease in ventilated neonates: a randomized trial. Pediatrics (1999) 104:91–99.
   PubMed Web of Science ®Google Scholar
• SOLL RF, FOR THE VERMONT OXFORD NETWORK STEROID STUDY GROUP: Early postnatal dexametha-sone therapy for the prevention of chronic lung disease. Pediatr. Res. (1999) 45:226 Abstract.
   Google Scholar
• WATTERBERG KL, GERDES JS, GIFFORD KL, UN HM: Prophylaxis against early adrenal insufficiency to prevent chronic lung disease in premature infants. Pediatr. Res. (1999) 45:232 Abstract.
   Google Scholar
• •Meeting abstract: Very interesting proposal for early preven-tion of CLD with physiologic hydrcortisone replacement based on the hypothesis that very premature infants may have relative adrenal insufficiency which predisposes to CLD.
   Google Scholar
• NG PC: The effectiveness and side effects of dexamethasone in preterm infants with bronchopul-monary dysplasia. Arch. Dis. Child (1993) 68:330–336.
   PubMed Web of Science ®Google Scholar
• WEILER HA, PAES B, SHAH JK, ATKINSON SA: Longitu-dinal assessment of growth and bone mineral accretion in prematurely born infants treated for chronic lung disease with dexamethasone. Early Hum. Dev. (1997) 47:271–286.
   PubMed Web of Science ®Google Scholar
• LEITCH CA, AHLRICHS JA, KARN CA, DENNE SC: Growth reduction during dexamethasone therapy is not caused by increased energy expenditure. Pediatr. Res. (1996) 39:314.Abstract.
   Google Scholar
• BROWNLEE KG, NG PC, HENDERSON MJ, SMITH M, GREEN JH, DEAR PRF: Catabolic effect of dexametha-sone in the preterm baby. Arch. Dis. Child (1992) 67:1–4.
   PubMed Web of Science ®Google Scholar
• FORD LR, WILLI SM, HOLLIS BW, WRIGHT NM: Suppres-sion and recovery of the neonatal hypothalamic-pituitary-adrenal axis after prolonged dexamethasone therapy. J. Pediatr. (1997) 131:722–726.
   PubMed Web of Science ®Google Scholar
• ALKALAY AL: Evaluation of hypothalamic-pituitary-adrenal axis in premature infants treated with dexamethasone. Am. J. Perinatol. (1996) 13:473–477.
   PubMed Web of Science ®Google Scholar
• WILSON DM, BALDWIN RB, ARIAGNO RL: A randomized, placebo-controlled trial of effects of dexamethasone axis in preterm infants. J. Pediatr. (1988) 113:764–768.
   PubMed Web of Science ®Google Scholar
• RIZVI ZB, ANIOL HS, MYERS TF, ZELLER WP, FISHER SG, ANDERSON CL: Effects of dexamethasone on the hypothalamic-pituitary-adrenal axis in preterm infants. J. Pediatr. (1992) 120:961–965.
   PubMed Web of Science ®Google Scholar
• NG PC, WONG GW, LAM CW et al.: Pituitary-adrenal suppression and recovery in preterm very low birth weight infants after dexamethasone treatment for bronchopulmonary dysplasia. J. Clin. Endocrinof Metab. (1997) 82:2429–2432.
   PubMed Web of Science ®Google Scholar
• KORTE C, STYNE D, MERRITT A, MAYES D, WERTZ A, HELBOCK HJ: Adrenocortical function in the very low birth weight infant: improved testing sensitivity and association with neonatal outcome. J. Pediatr. (1996) 128:257–263.
   PubMed Web of Science ®Google Scholar
• •Excellent study and discussion of assessing neonatal HPA axis.
   Google Scholar
• NG PC, BROWNLEE KG, DEAR PRF: Gastroduodenal perforation in preterm babies treated with dexamethasone for bronchopulmonary dysplasia. Arch. Dis. Child (1991) 66:1164–1166.
   PubMed Web of Science ®Google Scholar
• BENSKY AS, KOTHADIA JM, COVITZ W: Cardiac effectsof dexamethasone in very low birth weight infants. Pediatrics (1996) 97:818–821.
   PubMed Web of Science ®Google Scholar
• EVANS N: Cardiovascular effects of dexamethasone in the preterm infant. Arch. Dis. Child (1994) 70:F25–F30.
   Google Scholar
• SKELTON R, GILL AB, PARSONS JM: Cardiac effects of short course dexamethasone in preterm infants. Arch. Dis. Child Fetal Neonatal Ed. (1998) 78:F133–F137.
   Google Scholar
• BATTON DG, ROBERTS C, TRESE M, MAISELS MJ: Severeretinopathy of prematurity and steroid exposure. Pediatrics (1992) 90:534–536.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN R, SIASSI B, DELEMOS RA: Severe retino-pathy of prematurity in extremely low birth weight infants after short-term dexamethasone therapy. J. Perinatol. (1995) 15:178–182.
   PubMedGoogle Scholar
• ANDERSON C, RICHARDSON D, STEWART J, LEVITON A:Does dexamethasone increase the risk of retinopathy of prematurity (ROP)? Pediatr. Res.(1994) 35:263. Abstract.
   Google Scholar
• WRIGHT K, WRIGHT SP: Lack of association of glucocor-ticoid therapy and retinopathy of prematurity. Arch. Pediatr. Adolesc. Med. (1994) 148:848–852.
   PubMed Web of Science ®Google Scholar
• KLEIN KA, CUCULICH PS, MELLEN BG, SHENAI JP: Effectof dexamethasone on retinopathy of prematurity in preterm infants. Pediatr. Res. (1999) 45:205 Abstract.
   Google Scholar
• MUKWAYA G: Immunosuppressive effects and infections associated with corticosteroid therapy. Pediatr. Infec. Dis. J. (1988) 7:499–504.
   PubMed Web of Science ®Google Scholar
• PEREZ EM, WEISMAN LE: Dexamethasone concentra-tion affects the neutrophil mediated bacterial killing of group B streptococcus. Pediatr. Res. (1996) 39:224 Abstract.
   Google Scholar
• KINGO ARM, SCHEIFELE D, PENDRAY M, WAISMAN D AND MILNER R: Does treatment with dexamethasone affect the immunological response to antigenic challenge of infants born preterm? Pediatr. Res. (1996) 39:289 Abstract.
   Google Scholar
• ROBINSON MJ, CAMPBELL F, POWELL P, SIMS D, THORNTON C: Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease. Arch. Dis. Child Fetal Neonatal Ed. (1999) 80:F69–F71.
   Google Scholar
• TSCHANZ SA, DAMKE BM, BURRI PH: Influence of postnatally administered glucocorticoids on rat lung growth. Biol. Neonate (1995) 68:229–245.
   PubMedGoogle Scholar
• SHAPIRO S: Some physiological, biochemical andbehavioural consequences of neonatal hormone administration: cortisol and thyroxin. Gen. Comp. Endocrinol. (1968) 10:214–228.
   PubMed Web of Science ®Google Scholar
• HOWARD E, BENJAMINS JA: DNA, ganglioside and sulfatide in brains of rats given corticosterone in infancy, with an estimate of cell loss during develop-ment. Brain. Res. (1975) 92:73–87.
   PubMed Web of Science ®Google Scholar
• WEICHSEL ME: The therapeutic use of glucocorticoidhormones in the perinatal period: potential neurologic hazards. Ann. Neurol. (1977) 2:364–366.
   PubMed Web of Science ®Google Scholar
• BENESOVA 0, PAVLIK A: Perinatal treatment withglucocorticoid and the risk of maldevelopment of the brain. Neuropharmacology (1989) 28:89–97.
   PubMed Web of Science ®Google Scholar
• YEH TF, UN YJ, HUANG CC, CHEN YJ, TSAI WF, LIEN YJ:Early postnatal (12 hrs) dexamethasone therapy for prevention of BPD in preterm infants with RDS- a two-year follow-up study. Pediatrics (1998) 101(5): hap ://www. pediatrics. org/cgi/content/ful1/101/5/e7
   Google Scholar
• O'SHEA TM, KOTHADIA JM, KLINEPETER KL et al: Randomized placebo-controlled trial of a 42-day tapering course of dexamethasone to reduce the duration of ventilator dependency in very low birth weight infants: outcome of study participants at 1-year adjusted age. Pediatrics (1999) 104:15–21.
   PubMed Web of Science ®Google Scholar
• KONIG P, SHATELY M, LEVINE C, MASHINNEY TP: Clinical observations of nebulised flunisolide in infants and young children with asthma and bronchopulmonary dysplasia. Pediatr. Pulmonol (1992) 13:209–214.
   PubMed Web of Science ®Google Scholar
• CLOUTIER MM, MCLELLAN N: nebulised steroid therapy in bronchopulmonary dysplasia. Pediatr. Pulmonol. (1993) 15:111–116.
   PubMed Web of Science ®Google Scholar
• LIU EA, HELDT GP: A trial of the safety of inhaled beclomethasone in ventilator-treated neonates. J. Pediatr. (1996) 129:154–156.
   PubMed Web of Science ®Google Scholar
• GAL P, DIAZ PR, RANSOM JL, THORSON DW: Beclomethasone for treating premature infants with bronchopulmonary dysplasia. J. Pediatr. (1993) 123:490–491.
   PubMed Web of Science ®Google Scholar
• DIMITRIOU G, GREENOUGH A, GIFFIN FJ, KAVADIA V: Inhaled versus systemic steroids in chronic oxygen dependency of preterm infants. Eur. J. Pediatr. (1997) 156:51–55.
   PubMed Web of Science ®Google Scholar
• •Assessment of onset of effect of systemic versus inhaled steroid therapy.
   Google Scholar
• SUCHOMSKI SJ, CUMMINGS JJ: Randomized trial of inhaled (NH) vs. intravenous (IV) steroid in ventilator dependent preterm infants. Pediatr. Res. (1996) 39:247 Abstract.
   Google Scholar
• •Research meeting abstract comparing effect of systemic dexamethasone therapy with inhaled steroid therapy.
   Google Scholar
• ARNON S, GRIGG J, SILVERMAN M: Effectiveness of budesonide aerosol in ventilator-dependent preterm babies: a preliminary report. Pediatr. Pulmonol. (1996) 21:231–235.
   PubMed Web of Science ®Google Scholar
• COLE CH, COLTON T, SHAH BL et al: Early inhaled glucocorticoid therapy for prevention of bronchopul-monary dysplasia. N Engl. J. Med. (1999) 340:1005–1010.
   PubMed Web of Science ®Google Scholar
• •Large randomized trial reflecting some benefits in respira-tory outcomes in infants treated with prophylactic inhaled beclomethasone therapy, but no reduction in CLD.
   Google Scholar
• GUPTA GK, COLE CH, ABBASI S et al.: Effect of beclomethasone therapy on tracheal aspirate interleukin-8 and interleukin-1 receptor antagonist in preterm ventilated infants at risk for bronchopul-monary dysplasia (BPD). Pediatr. Res.(1999) 45:303 Abstract.
   Google Scholar
• •Rcent research meeting abstract reflecting less tracheal aspirate inflammation in beclomethasone treated infants.
   Google Scholar
• ABBASI S, COLE CH, FRANTZ I, YKORUK R, GERDES J: Effect of early glucocorticoid therapy on tracheobron-chial lesions I mechanically ventilated preterm infants. Pediatr. Res. (1999) 45:179 (Abstract).
   Google Scholar
• •Recent research meeting abstract showing inhaled beclomethasone is associated with less tracheobronchial mucosal injury.
   Google Scholar
• FOK TF, LAM K, DOLOVICH M et al.: Randomized controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome. Arch. Dis. Child Fetal Neonatal Ed. (1999) 80:F203–F208.
   Google Scholar
• •Interesting pilot study of prophylactic fluticasone therapy in infants at risk for CLD.
   Google Scholar
• NG PC, FOK TF, WONG GWK et al: Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J. Clin. Endo. Metab. (1998) 83:2390–2393.
   PubMed Web of Science ®Google Scholar
• •Interesting study and discussion of CRH stimulation test for P-A assessment.
   Google Scholar
• DOLOVICH M: Aerosol delivery to children: What to use, How to choose. Pediatric Pulmonol. (1999) 18:79–82.
   Google Scholar
• •Excellent review and discussion regarding aerosol delivery to infants and children.
   Google Scholar
• BISGAARD H: Delivery of inhaled medication to children. J. Asthma (1997) 34 (6):443–467.
   PubMed Web of Science ®Google Scholar
• •Detailed review regarding aerosol delivery to infants and children.
   Google Scholar
• DOLOVICH M: Changing delivery methods for obstruc-tive lung diseases. Curr. Opin. Pulm. Med. (1997) 3(3):177–189.
   PubMedGoogle Scholar
• •Updated review of aerosol delivery systems and new formulations of aerosol drugs.
   Google Scholar